ls301
Small moleculeexperimentalImaging agent
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2019 (NCT04105062)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07276789 | Phase 2 | Dec 8, 2025 | Integro Theranostics |
| NCT06713564 | Phase 1 | Nov 7, 2024 | Integro Theranostics |
| NCT05900986 | Phase 1/Phase 2 (Phase 2) | Jul 14, 2023 | Integro Theranostics |
| NCT02807597 | Phase 1/Phase 2 (Phase 2) | Feb 18, 2020 | The University of Texas, Dallas |
| NCT04105062 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2019 | Washington University in St. Louis |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Integro Theranostics | For profit | 3 | 3 | 2 | 2023 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2019 |
3 organizations
Page 1 / 1